0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > CD52

CD52

Brief Information

Name:CAMPATH-1 antigen
Target Synonym:Epididymis Secretory Sperm Binding Protein Li 171mP,CD52 Antigen (CAMPATH-1 Antigen),Epididymal Secretory Protein E5,He5,CDW52 Antigen (CAMPATH-1 Antigen),CD52 Antigen,HEL-S-171mP,EDDM5,CD52,CDw52,Cambridge pathology 1 antigen,Human epididymis-specific protein 5,CAMPATH-1 antigen,CD52 Molecule
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

Par statut du produit :
Par catégorie de produit :
Par espèce :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
CD2-H82E8 Human Biotinylated Human CD52 Protein, His,Avitag™
CD2-H82E8-structure
CD2-H82E8-sds
CD2-H525a Human Human CD52 Protein, Fc Tag
CD2-H525a-structure
CD2-H525a-sds
CD2-H82F3 Human Biotinylated Human CD52 Protein, Fc,Avitag™
CD2-H82F3-structure
CD2-H82F3-sds
ACRO Quality

Part of Bioactivity data

CD2-H82E8-SPR
 CD52 SPR

Anti-Human CD52 MAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Biotinylated Human CD52, His,Avitag (Cat. No. CD2-H82E8) with an affinity constant of 71.8 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CD2-H82E8-BLI
 CD52 BLI

Loaded Biotinylated Human CD52, His,Avitag (Cat. No. CD2-H82E8) on SA Biosensor, can bind Anti-Human CD52 MAb (Human IgG1) with an affinity constant of 137 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

CDW52,HE5,CD52,CAMPATH-1 antigen

Background

CAMPATH-1 antigen, also known as cluster of differentiation 52 (CD52), is a glycoprotein that in humans is encoded by the CD52 gene.It is widely expressed on the cell surface of immune cells, such as mature lymphocytes, natural killer cells (NK), eosinophils, neutrophils, monocytes/macrophages, and dendritic cells (DCs).ligation of cell surface CD52 molecules may offer costimulatory signals for T-cell activation and proliferation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Alemtuzumab LDP-03; GZ-402673 Approved Genzyme Corp, Bayer AG Campath, Lemtrada, MabCampath United States Multiple Sclerosis Genzyme Corp 2001-05-07 Myositis, Inclusion Body; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Waldenstrom Macroglobulinemia; Lymphoma; Leukemia, Prolymphocytic, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Lymphoproliferative Disorders; Peritoneal Neoplasms; Sezary Syndrome; Pancytopenia; Lymphoma, T-Cell, Peripheral; Multiple Sclerosis; Rejection of organ transplantation; Leukemia-Lymphoma, Adult T-Cell; Myelodysplastic Syndromes; Hodgkin Disease; Graft vs Host Disease; Kidney Diseases; Rejection of renal transplantation; Hematologic Neoplasms; Ovarian Neoplasms; Diabetes Mellitus, Type 1; Bone marrow transplant rejection; Leukemia; Multiple Sclerosis, Relapsing-Remitting Details
Alemtuzumab LDP-03; GZ-402673 Approved Genzyme Corp, Bayer AG Campath, Lemtrada, MabCampath United States Multiple Sclerosis Genzyme Corp 2001-05-07 Myositis, Inclusion Body; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Waldenstrom Macroglobulinemia; Lymphoma; Leukemia, Prolymphocytic, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Lymphoproliferative Disorders; Peritoneal Neoplasms; Sezary Syndrome; Pancytopenia; Lymphoma, T-Cell, Peripheral; Multiple Sclerosis; Rejection of organ transplantation; Leukemia-Lymphoma, Adult T-Cell; Myelodysplastic Syndromes; Hodgkin Disease; Graft vs Host Disease; Kidney Diseases; Rejection of renal transplantation; Hematologic Neoplasms; Ovarian Neoplasms; Diabetes Mellitus, Type 1; Bone marrow transplant rejection; Leukemia; Multiple Sclerosis, Relapsing-Remitting Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Alemtuzumab biosimilar (Zhangjiang Biotechnology) Phase 2 Clinical Shanghai Zhangjiang Biotechnology Co Ltd Leukemia, Lymphocytic, Chronic, B-Cell Details
ALLO-647 ALLO-647 Phase 2 Clinical Allogene Therapeutics Inc Lymphoma, B-Cell; Carcinoma, Renal Cell; Multiple Myeloma; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell Details
Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology) Phase 1 Clinical Lanzhou Institute Of Biological Products Co Ltd, Shanghai Taiyin Biotechnology Co Ltd Leukemia, B-Cell; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic Details
Alemtuzumab biosimilar(BioXpress) BX-1523; BXT-1523 Clinical Bioxpress Therapeutics Sa Multiple Sclerosis; Leukemia, B-Cell Details
Alemtuzumab biosimilar (Zhangjiang Biotechnology) Phase 2 Clinical Shanghai Zhangjiang Biotechnology Co Ltd Leukemia, Lymphocytic, Chronic, B-Cell Details
ALLO-647 ALLO-647 Phase 2 Clinical Allogene Therapeutics Inc Lymphoma, B-Cell; Carcinoma, Renal Cell; Multiple Myeloma; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell Details
Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology) Phase 1 Clinical Lanzhou Institute Of Biological Products Co Ltd, Shanghai Taiyin Biotechnology Co Ltd Leukemia, B-Cell; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic Details
Alemtuzumab biosimilar(BioXpress) BX-1523; BXT-1523 Clinical Bioxpress Therapeutics Sa Multiple Sclerosis; Leukemia, B-Cell Details

This web search service is supported by Google Inc.

totop

Laisser un message